Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 5/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756309 | 1.00 | PDE4B (0.48) | PDE4BAGTR2PDE4APDE4CPDE4D | |
| SCHEMBL5350761 | 0.93 | PDE4B (0.51) | PDE4BAGTR2PDE4APDE4CPDE4D | |
| SCHEMBL5756458 | 0.92 | PDE4B (0.51) | PDE4BAGTR2PDE4APDE4CPDE4D | |
| SCHEMBL5759093 | 0.91 | PDE4B (0.50) | PDE4BAGTR2PDE4APDE4CPDE4D | |
| SCHEMBL5355796 | 0.91 | PDE4B (0.54) | PDE4BAGTR2PDE4APDE4CPDE4D | |
| SCHEMBL5355052 | 0.90 | PDE4B (0.49) | PDE4BAGTR2PDE4APDE4CPDE4D | |
| SCHEMBL5791891 | 0.90 | PDE4B (0.49) | PDE4BAGTR2PDE4APDE4CPDE4D | |
| SCHEMBL5356940 | 0.90 | PDE4B (0.48) | PDE4BAGTR2PDE4APDE4CPDE4D | |
| SCHEMBL4524186 | 0.89 | PDE4B (0.49) | PDE4BAGTR2PDE4APDE4CPDE4D | |
| SCHEMBL5349965 | 0.89 | PDE4B (0.46) | PDE4BAGTR2PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242400-B1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORP (US) | 2006-05-03 | — | — | EP | claimed |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2004-08-05 | — | — | US | claimed |
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION | 2004-02-05 | — | — | US | claimed |
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1242400-B1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
| US-6998416-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2004-08-05 | — | — | US | disclosed |
| US-6716871-B2 | OBESITY; INFLAMMATORY DISEASES, DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, CENTRAL NERVOUS SYSTEM DISORDERS; 3-HYDROXYALKYL-4-DIALKOXYPHENYL-SUBSTITUTED PYRROLIDINES | ICOS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-6423710-B1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE7A | PDE4B 2/4885AGTR2 2380/4885PDE4A 1/4885 |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | PDE4B 2/4885AGTR2 2380/4885PDE4A 1/4885 |
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | PDE4B 2/4885AGTR2 2380/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.